MYC and plasma cell myeloma: DCR-MYC, a synthetic siRNA targeting MYC encapsulated in EnCore lipid nanoparticles, was evaluated in patients with advanced solid tumors, multiple myeloma, and lymphoma, demonstrating a favorable safety profile (NCT02110563).